Pluspunten
Over the past year, the company has undergone a noticeable and positive evolution, with a much sharper strategic focus and a more deliberate approach to how time, talent, and resources are deployed. There is a strong and visible commitment to advancing the programs with the highest potential to meaningfully impact patients, paired with an increasing emphasis on scientific excellence, operational rigor, and disciplined execution. Teams across the organization are deeply mission-driven, collaborative, and united by a genuine sense of responsibility to patients, which consistently guides decision-making at every level. Leadership is engaged, approachable, and transparent, and has been thoughtful and decisive in setting priorities as programs progress into critical clinical, regulatory, and company-defining stages. This combination of clarity, alignment, and purpose has created real momentum and a growing sense of optimism and excitement about the company’s future and the impact its work can have.
Minpunten
As with any growing biotech, the pace can be intense and change is constant. Priorities can shift quickly as data emerge or external factors evolve, which can be challenging at times but this reflects the reality of working at the forefront of science.